21245097|alpha|C0439095^C2003941^C2350010|start=0|end=5|CONC
21245097|beta|C1552649^C2004068^C0439096|start=14|end=18|CONC
21245097|therapy|C0039798^C0087111|start=41|end=48|PROC^CONC
21245097|prostate cancer|C0376358^C0600139^C2984325^C3541264|start=60|end=75|DISO^CONC
21245097|model|C0026336^C3714583^C3274659^C0026339^C3161035|start=76|end=81|DEVI^CONC
21245097|recurrent prostate cancer|C0278838|start=141|end=166|DISO
21245097|challenge|C0805586^C3274764^C0798503|start=178|end=187|PROC^PHYS^CONC
21245097|conventional treatment|C2945704|start=191|end=213|PROC
21245097|address|C1578437^C2741676^C0376649^C1547327^C1442065^C1578436|start=234|end=241|PHYS^CONC
21245097|disease|C0012634|start=275|end=282|DISO
21245097|use of|C1524063|start=284|end=290|CONC
21245097|alpha|C0439095^C2003941^C2350010|start=291|end=296|CONC
21245097|radionuclide therapy|C0203608|start=297|end=317|PROC
21245097|considered|C0750591|start=321|end=331|CONC
21245097|highly|C0205250|start=337|end=343|CONC
21245097|effective|C1704419^C1280519|start=344|end=353|CONC
21245097|treatment|C1705169^C0039798^C1533734^C3161471^C1522326^C3538994^C0087111|start=354|end=363|PROC^CONC
21245097|applications|C0185125|start=372|end=384|PROC
21245097|due to|C0678226|start=385|end=391|CONC
21245097|range|C3542016^C1514721^C2348147|start=404|end=409|CONC
21245097|cytotoxicity|C1551412^C0596402|start=424|end=436|DISO^PROC
21245097|alpha|C0439095^C2003941^C2350010|start=440|end=445|CONC
21245097|compared|C1707455|start=459|end=467|ACTI
21245097|beta|C1552649^C2004068^C0439096|start=473|end=477|CONC
21245097|considered|C0750591|start=500|end=510|CONC
21245097|alpha|C0439095^C2003941^C2350010|start=514|end=519|CONC
21245097|emitter|C1707907|start=520|end=527|OBJC
21245097|high|C2700149^C1561957^C0205250^C1299351^C1561958|start=533|end=537|CONC
21245097|clinical|C1611832^C1555900^C1608518^C3272565^C0205210|start=538|end=546|CONC
21245097|potential|C3245505|start=547|end=556|CONC
21245097|due to|C0678226|start=558|end=564|CONC
21245097|short|C1806781^C2350002^C1282927|start=569|end=574|CONC
21245097|half-life|C0018517|start=575|end=584|CONC
21245097|minutes|C0700321^C0439232^C1282918|start=591|end=598|CONC
21245097|matched|C0150103^C1708943|start=611|end=618|PROC^CONC
21245097|use|C1947944^C0042153^C0457083|start=623|end=626|CONC
21245097|alpha|C0439095^C2003941^C2350010|start=660|end=665|CONC
21245097|therapy|C0039798^C0087111|start=666|end=673|PROC^CONC
21245097|limited|C0439801^C3542948|start=693|end=700|CONC
21245097|knowledge|C0376554|start=701|end=710|CONC
21245097|available|C0470187|start=711|end=720|CONC
21245097|context|C0542559|start=733|end=740|CONC
21245097|use|C1947944^C0042153^C0457083|start=744|end=747|CONC
21245097|study|C0947630^C2603343^C0557651^C0008972^C1705923^C1880229|start=757|end=762|PROC^OBJC^CONC
21245097|novel|C0205314^C0679622|start=768|end=773|CONC
21245097|labeled|C1708632|start=782|end=789|CONC
21245097|peg|C0176751|start=805|end=808|PROC
21245097|bombesin|C1333714|start=812|end=820|GENE
21245097|compared|C1707455|start=902|end=910|ACTI
21245097|beta|C1552649^C2004068^C0439096|start=925|end=929|CONC
21245097|emitter|C1707907|start=930|end=937|OBJC
21245097|labeled|C1708632|start=939|end=946|CONC
21245097|independent|C0085862^C1608386^C1549571|start=978|end=989|CONC
21245097|prostate carcinoma|C0600139|start=990|end=1008|DISO
21245097|xenograft model|C1520166|start=1009|end=1024|DISO
21245097|tumor|C0027651^C1578706|start=1031|end=1036|DISO^CONC
21245097|maximum tolerated dose|C0752079|start=1139|end=1161|CONC
21245097|mtd|C1417393^C0752079|start=1163|end=1166|GENE^CONC
21245097|dosimetry|C0034603|start=1190|end=1199|PROC
21245097|of each|C1882141|start=1200|end=1207|CONC
21245097|agent|C1521826|start=1208|end=1213|CONC
21245097|left|C0205091^C1552822|start=1229|end=1233|CONC
21245097|given|C3244317^C1442162^C1550718^C1947971|start=1252|end=1257|CONC
21245097|mtd|C1417393^C0752079|start=1297|end=1300|GENE^CONC
21245097|mbq|C0556640|start=1347|end=1350|CONC
21245097|mci|C3463911^C1270972^C0560005|start=1357|end=1360|DISO^GENE^CONC
21245097|mtd|C1417393^C0752079|start=1399|end=1402|GENE^CONC
21245097|mbq|C0556640|start=1410|end=1413|CONC
21245097|mci|C3463911^C1270972^C0560005|start=1417|end=1420|DISO^GENE^CONC
21245097|dose|C0869039^C0178602|start=1432|end=1436|CONC
21245097|levels|C0441889|start=1437|end=1443|CONC
21245097|effective|C1704419^C1280519|start=1505|end=1514|CONC
21245097|time|C0040223^C1548318^C1547403^C3541383|start=1552|end=1556|CONC
21245097|minimal|C0547040^C1524031|start=1584|end=1591|CONC
21245097|slight|C2937276^C2945599|start=1612|end=1618|CONC
21245097|marked|C1706089^C0522501|start=1637|end=1643|CONC
21245097|kidney|C1514845^C1278978^C0227665^C0022646|start=1644|end=1650|ANAT
21245097|damage|C2681922^C0010957^C1883709|start=1651|end=1657|DISO^GENE^CONC
21245097|weeks|C0439230|start=1667|end=1672|CONC
21245097|preclinical|C1709630|start=1694|end=1705|CONC
21245097|data|C3245479^C1511726|start=1706|end=1710|DEVI^CONC
21245097|alpha|C0439095^C2003941^C2350010|start=1725|end=1730|CONC
21245097|therapy|C0039798^C0087111|start=1731|end=1738|PROC^CONC
21245097|beta|C1552649^C2004068^C0439096|start=1804|end=1808|CONC
21245097|therapy|C0039798^C0087111|start=1809|end=1816|PROC^CONC
21245097|better|C1550462^C0332272|start=1856|end=1862|CONC
21245097|safety|C0036043^C1705187|start=1863|end=1869|PROC^PHEN
21245097|profile|C2003903^C1979963|start=1870|end=1877|PROC^CONC
21245097|possible|C0332149^C1705910^C2362652|start=1914|end=1922|CONC
21245097|new|C0205314^C1553390^C2986548^C1578513|start=1923|end=1926|PROC^CONC
21245097|approach|C0449445|start=1927|end=1935|CONC
21245097|use|C1947944^C0042153^C0457083|start=1940|end=1943|CONC
21245097|alpha|C0439095^C2003941^C2350010|start=1977|end=1982|CONC
21245097|therapy|C0039798^C0087111|start=1983|end=1990|PROC^CONC
21245097|treating|C1522326|start=1991|end=1999|CONC
21245097|recurrent prostate cancer|C0278838|start=2000|end=2025|DISO
